BioSpace News Archive

Roivant Sciences announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 in ulcerative colitis.

Azitra, Inc. announced the closing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $7,500,000, before deducting underwriting discounts and offering expenses.

AssayQuant® Technologies, Inc. introduces KinSight™ Kinome Profiling Services providing superior results including kinetic insights into selectivity and mechanisms of action for drug discovery.

Avidity Biosciences, Inc. announced that on June 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 23,650 shares of its common stock and 11,825 restricted stock units to four new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.

Panbela Therapeutics, Inc. announced the closing of its previously announced public offering of 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock at a purchase price of $3.75 per share and associated Public Warrants and $3.749 per pre-funded warrant and associated Public Warrants.

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.

Avid Bioservices, Inc. (NASDAQ:CDMO) today announced financial results for the fourth quarter and full fiscal year ended April 30, 2023.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the gross proceeds from the non-brokered private placement are to commence the buildout of production of ACP-01 via a contract in the form of a production facility cotenancy agreement negotiated by the Issuer, pay current filing, regulatory, and finder fees in connection with the offering, and for general working capital purposes.

BioCity Biopharma announced the initiation of a randomized, placebo-controlled Phase 2 clinical trial of its novel, oral endothelin A -receptor selective antagonist, SC0062, with the enrollment of two patients with IgA nephropathy (IgAN) in China (NCT05687890).

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040.